Breaking News

Biogen Idec To Acquire Fumapharm AG

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec has agreed to acquire Fumapharm AG, a developer of therapeutics derived from fumaric acid esters for patients with high unmet medical need. The company has two products: Fumaderm, a commercial product available in Germany for the treatment of psoriasis, and BG-12, a clinical-stage product that has been jointly developed with Biogen Idec. An oral fumarate, BG-12 is being investigated for the treatment of multiple sclerosis (MS) and psoriasis. “This acquisition supports our ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters